Ships within 24 hours on business days · +10% with Bank Pay

CJC-1295 + Ipamorelin (5mg/5mg)

Shop

CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 DAC Bodybuilding: What the Research Shows

45 WORDS

Short answer

Most CJC-1295 DAC bodybuilding questions reduce to a single question about resistance training, and the published literature answers it plainly: mechanical loading is the stimulus that drives contractile protein accretion, and growth hormone axis compounds studied without a training component have not reproduced that effect.

Most CJC-1295 DAC bodybuilding questions reduce to a single question about resistance training, and the published literature answers it plainly: mechanical loading is the stimulus that drives contractile protein accretion, and growth hormone axis compounds studied without a training component have not reproduced that effect. In research models that pair Ipamorelin with CJC-1295 without DAC, resistance exercise is not background, it is the variable the growth hormone axis is being tested against. Controlled trials of recombinant growth hormone in athletic populations report changes in lean body mass that are not matched by gains in strength or power, and reviewers attribute part of that lean mass signal to fluid rather than to muscle protein. This page summarizes what measured endpoints in the published record show, where the evidence runs out, and where CJC-1295 sits with anti-doping authorities and regulators. Real Peptides supplies research-use-only compounds and provides no guidance on use.

Is resistance training required in research combining Ipamorelin and CJC-1295 without DAC?

In the published evidence, yes: muscle fiber hypertrophy is attributed to mechanical loading, and growth hormone axis stimulation on its own has not been shown to substitute for it. The exercise physiology literature describes resistance loading as the proximate trigger for myofibrillar protein synthesis, acting through mechanotransduction and downstream anabolic signalling within the loaded fibers. Growth hormone and insulin-like growth factor 1 are systemic signals, and the trials that raised them without a loading stimulus report a different pattern of outcomes than training studies do.

The clearest illustration comes from the recombinant growth hormone literature rather than from CJC-1295 itself. Systematic review: the effects of growth hormone on athletic performance, published in Annals of Internal Medicine in 2008, pooled controlled studies in physically fit participants and reported that lean body mass increased in the active arms while strength and exercise capacity did not improve measurably. The reviewers noted that a portion of the lean mass change is consistent with fluid retention and extracellular water expansion rather than with new contractile tissue, which is exactly the distinction a body composition researcher cares about.

That finding sets the expectation for GHRH analog work. CJC-1295 without DAC is a GHRH receptor agonist: it acts upstream, prompting the pituitary to release its own growth hormone, and it is still bounded by somatostatin tone and by negative feedback from circulating insulin-like growth factor 1. Research suggests a secretagogue can amplify a pulse; it does not create the local mechanical signal that directs amino acids into myofibrils. For a study design, this means a loading arm is not an optional add-on. Without it, the measurable result is likely to be a hormonal and fluid compartment change, not a strength or cross-sectional area change. Questions framed as personal training programs fall outside what a research-use-only supplier addresses, and Real Peptides does not answer them.

What is the DAC modification and how does it change CJC-1295?

DAC stands for Drug Affinity Complex, a chemical modification that lets the peptide bind covalently to circulating albumin, which greatly extends how long the molecule stays in circulation. CJC-1295 is built on the first 29 amino acids of growth hormone releasing hormone, the fragment that carries receptor activity, with amino acid substitutions that resist enzymatic breakdown. The no-DAC version is that stabilized fragment alone and is cleared quickly, producing a short, pulse-like stimulus at the GHRH receptor. The DAC version carries a reactive linker that attaches to a lysine residue on serum albumin, so the peptide is no longer cleared on the timescale of minutes.

The practical consequence for research design is the shape of the exposure curve. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults, published in the Journal of Clinical Endocrinology and Metabolism in 2006, reported that elimination of the albumin-bound form was measured in days rather than minutes, and that growth hormone and insulin-like growth factor 1 concentrations remained above baseline well beyond the first day in the active arms. The no-DAC form, by contrast, is studied as a transient stimulus intended to work with the body's existing pulse pattern.

This matters because endocrine physiology describes growth hormone secretion as pulsatile, with large nocturnal bursts and low interpulse concentrations, and research suggests that the pattern of exposure, not only the total amount, influences hepatic and peripheral responses. Sustained elevation and pulsatile elevation are not interchangeable experimental conditions. A study comparing the two forms is comparing exposure profiles, and the honest reading of the record is that the body composition consequences of those two profiles have not been separated in controlled human trials. Interest in the DAC form in strength sport contexts rests on the sustained insulin-like growth factor 1 signal, which remains a surrogate marker rather than a measured tissue outcome.

What did the published CJC-1295 clinical research actually measure?

The core published human work on CJC-1295 measured hormones and safety, not muscle. The 2006 Journal of Clinical Endocrinology and Metabolism report described placebo-controlled work in healthy adults in which assigned trial amounts were compared across groups and the measured endpoints were serum growth hormone, insulin-like growth factor 1, pharmacokinetic parameters and standard tolerability monitoring. The paper reports that growth hormone concentrations rose and that insulin-like growth factor 1 increases scaled with the assigned amounts and persisted for a period of days, with the effect sustained across the trial's step-up phase.

What the paper does not contain is as relevant as what it does. There is no dual-energy X-ray absorptiometry body composition arm, no strength testing, no muscle biopsy, no nitrogen balance work and no trained-athlete population. The participants were healthy adults studied over a short window, sample sizes were small by the standards of a body composition trial, and there was no exercise intervention. Treating that dataset as evidence for hypertrophy is an extrapolation across both population and endpoint.

This is the central honesty problem for the performance literature on this compound. The indexed clinical record describes what CJC-1295 does to a hormonal axis, and the claim that a given hormonal change produces measurable muscle in trained humans has to come from elsewhere. Insulin-like growth factor 1 is a reasonable pharmacodynamic marker, but studies report it as a readout of pituitary and hepatic response, not as a validated proxy for change in fat-free mass or in maximal force production.

There is also a reproducibility consideration. Because the published work focuses on the albumin-binding form, the no-DAC form has even less controlled human data behind it. Research models built on it generally borrow rationale from the broader GHRH analog literature, including work on other analogs of the same fragment, rather than from trials of that exact molecule. A study design should state that borrowing explicitly rather than implying direct evidence.

What do growth hormone trials report about lean body mass?

They report measurable increases in fat-free mass, with repeated caveats about what that compartment contains. Effects of human growth hormone in men over 60 years old, published in the New England Journal of Medicine in 1990, is the classic reference point: in older men with low insulin-like growth factor 1, the active arm showed an increase in lean body mass and a decrease in adipose tissue mass compared with controls, alongside changes in skin thickness. There was no exercise intervention and no strength endpoint, so the study speaks to body composition compartments and not to function.

Later syntheses added nuance. Systematic review: the safety and efficacy of growth hormone in the healthy elderly, published in Annals of Internal Medicine in 2007, pooled controlled studies in older adults and reported small changes in body composition, specifically a gain in lean mass and a loss of fat mass, without corresponding functional improvement, and with a higher frequency of adverse effects such as soft tissue swelling, joint discomfort and glucose dysregulation in the active arms. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized controlled trial, published in Annals of Internal Medicine in 2010, reported in young recreationally trained participants that the active arm showed reduced fat mass and increased lean body mass relative to placebo.

The interpretive thread across all three is compartmental. Dual-energy X-ray absorptiometry assigns water to the lean compartment, and growth hormone is well described as a sodium-retaining and fluid-expanding signal. Research suggests that fluid shifts, connective tissue and collagen turnover contribute to the measured lean mass increase, which is why reviewers consistently separate the body composition signal from the functional one. A GHRH analog study that reports only fat-free mass, without a hydration measure or a contractile endpoint, cannot distinguish these possibilities.

Does the literature show strength or power gains from growth hormone axis stimulation?

The controlled record does not support strength or power gains, and that is the most consistent negative finding in this field. The 2008 Annals of Internal Medicine systematic review of growth hormone and athletic performance reported no measurable improvement in strength or exercise capacity in the pooled active arms, despite the lean mass changes, and noted that lactate concentrations during exercise were higher in participants receiving growth hormone, along with more frequent soft tissue swelling and fatigue. The 2010 randomized controlled trial in recreational athletes reported an improvement in a sprint capacity endpoint in the active arms, with no measurable change in strength, power or endurance, and the sprint signal was accompanied by the body composition changes rather than by force production changes.

Two cautions apply to reading these results across to CJC-1295. First, these trials used recombinant growth hormone, which bypasses the pituitary entirely. A GHRH analog works upstream of the pituitary and is constrained by somatostatin tone, by pituitary somatotroph reserve and by feedback from insulin-like growth factor 1, so the achievable exposure differs in both magnitude and shape. Second, if the growth hormone trials themselves did not produce strength gains, a compound that produces a smaller and more physiological growth hormone signal has no plausible mechanistic path to a larger functional effect.

The literature does describe roles for the growth hormone and insulin-like growth factor 1 axis in connective tissue and collagen synthesis, in whole-body protein turnover and in fat oxidation, and research suggests those pathways are real even where the performance endpoints are flat. For study design, that argues for choosing endpoints the mechanism can plausibly move, such as tendon collagen markers, substrate oxidation or regional fat distribution, rather than one-repetition maximum strength, where the existing trials have already reported null findings.

What does research say about CJC-1295 weight loss and fat mass endpoints?

No controlled trial of CJC-1295 has reported body weight or fat mass as an endpoint, so claims about CJC-1295 weight loss rest on the wider growth hormone and GHRH analog literature rather than on direct evidence. What that wider literature reports is redistribution more than scale change: active arms tend to show less fat mass and more fat-free mass, with total body weight moving less than either compartment, partly because fluid retention offsets fat loss on the scale.

The most directly relevant GHRH analog evidence comes from tesamorelin, a stabilized analog of the same releasing hormone family. Metabolic effects of a growth hormone-releasing factor in patients with HIV, published in the New England Journal of Medicine in 2007, studied adults with excess abdominal fat and reported that the active arm showed a reduction in visceral adipose tissue measured by computed tomography relative to placebo, with insulin-like growth factor 1 rising as expected. Later work in that programme describes the visceral fat effect as dependent on continued exposure rather than persisting after it stops. That is a specific population with a specific fat distribution problem, and the result should not be read as a general statement about leanness in healthy or trained individuals.

Mechanistically, growth hormone is described in the literature as a lipolytic signal that promotes triglyceride breakdown in adipose tissue and shifts substrate use toward fat oxidation, with visceral depots appearing more responsive than the fat layer under the skin in several reports. That is a coherent rationale for studying fat distribution endpoints with GHRH analogs. It is not a rationale for expecting large changes in total body mass, and it says nothing about energy intake, which remains the dominant variable in any fat mass study and must be controlled or measured for the data to mean anything.

How does Ipamorelin differ mechanistically from CJC-1295?

Ipamorelin acts at a different receptor. It is a pentapeptide growth hormone secretagogue that binds the growth hormone secretagogue receptor, the same receptor later identified as the ghrelin receptor, whereas CJC-1295 binds the growth hormone releasing hormone receptor. Both converge on the somatotroph, but through separate signalling routes: the GHRH receptor couples to cyclic AMP driven pathways, while the secretagogue receptor signals through phospholipase C and intracellular calcium release, and research suggests it also reduces inhibitory somatostatin tone.

Ipamorelin, the first selective growth hormone secretagogue, published in the European Journal of Endocrinology in 1998, characterized the peptide in animal models and reported growth hormone release with selectivity, meaning the expected rises in adrenocorticotropic hormone, cortisol and prolactin seen with some earlier secretagogues were not observed at comparable activity in those models. That selectivity profile is the main reason the compound is used as a research tool when the goal is to probe the growth hormone axis without confounding stress hormone changes. The caveats are the usual ones: animal models, short observation, and endpoints that are hormonal rather than compositional.

In practical experimental terms, the two compounds change different features of the pulse. A GHRH receptor agonist is generally described as increasing the amount released per pulse, while a secretagogue receptor agonist is described as increasing pulse amplitude and frequency and as being sensitive to the prevailing somatostatin background. Neither bypasses the pituitary, so both are subject to the ceiling imposed by somatotroph capacity and by feedback. Background on each compound is collected on the CJC-1295 overview and the Ipamorelin overview pages, which cover identity and literature rather than use.

Why are GHRH analogs and secretagogues studied in combination?

The rationale is receptor complementarity: two agonists acting at distinct receptors on the same cell can produce a larger combined growth hormone release than either produces alone, and the secretagogue arm additionally lowers somatostatin restraint while the GHRH arm drives release. This synergy is described in the growth hormone secretagogue literature across several analog pairs, and it is the reason combination models remain common in endocrine pharmacology research.

The caution is that most combination claims in the body composition context are not backed by controlled trials of the specific pairing. The indexed literature does not appear to contain a randomized controlled trial of CJC-1295 together with Ipamorelin using body composition or strength endpoints in trained participants. What exists is mechanistic plausibility plus separate single-compound studies with hormonal endpoints. A research brief should say that rather than stitching the two literatures together and presenting the join as a finding.

A second caution concerns feedback. Insulin-like growth factor 1 and growth hormone both restrain further release through hypothalamic and pituitary feedback, so sustained stimulation of the axis does not produce an indefinitely rising signal. The 2006 CJC-1295 report describes an elevated plateau rather than a continuously climbing curve, and the broader endocrine literature suggests that desensitization and feedback limit what upstream stimulation can achieve. Combination models therefore need repeated sampling over time, not a single post-stimulus measurement, if they are to describe the axis response honestly.

Finally, combination work compounds the interpretation burden. With two active agents, any observed change in a composition or metabolic endpoint cannot be attributed to either compound without factorial design. Studies that use a combined arm without single-agent comparators generate hypothesis-level data only, which is a legitimate place to start but not a basis for mechanistic claims.

What role do training status, nutrition and sleep play in growth hormone axis research?

They are the dominant confounders, and a body composition study that does not control them cannot attribute its results to the compound. Growth hormone secretion is described as strongly tied to slow wave sleep, with the largest spontaneous pulses occurring in the first hours of the night, so sleep duration and architecture shift the baseline the study is measuring against. Energy availability matters just as much: insulin-like growth factor 1 is a nutrient-sensitive hormone, and the literature describes hepatic production falling under energy restriction and low protein availability, which can blunt the very endpoint a GHRH analog study is tracking.

Training status changes the response surface as well. Trained participants carry different baseline body composition, different insulin sensitivity and a different acute hormonal response to exercise than untrained participants, and the 2010 Annals of Internal Medicine trial deliberately used recreationally trained volunteers for that reason. Results from older adults with low baseline insulin-like growth factor 1, such as the 1990 New England Journal of Medicine study, cannot be read across to young trained individuals whose axis is already operating near its normal range. Studies report the largest compositional shifts where baseline function is lowest, which is a regression pattern as much as a drug effect.

Protein intake deserves separate mention because net protein balance, not hormone concentration, is what determines whether muscle protein accrues. The literature on resistance training describes feeding and loading as the two interventions that reliably shift fractional synthetic rate. Any study that reports a lean mass change without recording energy and protein intake has left its most powerful variable unmeasured. For the same reason, isolated statements about growth hormone axis compounds and leanness are weak evidence unless diet was standardized across arms.

What is the anti-doping and regulatory status of these compounds?

CJC-1295 and Ipamorelin are not approved by the United States Food and Drug Administration for any use, and growth hormone releasing factors and secretagogues fall within the prohibited peptide hormone and growth factor category of the World Anti-Doping Agency Prohibited List, which applies at all times, in competition and out of competition. Under the Federal Food, Drug, and Cosmetic Act, an unapproved new drug cannot be marketed for human use, and compounds supplied for laboratory research are sold on that basis only, with no claim of safety or effectiveness in people. Sport governing bodies that follow the World Anti-Doping Code treat the use and attempted use of these substances as anti-doping rule violations regardless of whether a performance benefit is demonstrated.

This regulatory position is independent of the scientific one. The published trials discussed on this page describe hormonal and compositional measurements in controlled settings with monitoring; they do not establish a sanctioned use, and the record of adverse effects reported in the growth hormone trials, including swelling, joint symptoms and impaired glucose handling, is part of why these compounds remain confined to research and specific approved indications for other molecules in the class.

Analytical science is also relevant to any laboratory working in this space. Anti-doping laboratories describe detection approaches based on biomarkers of the growth hormone axis and on direct detection of the releasing factors themselves, and the existence of those assays is the reason sport contexts are not hypothetical for method development laboratories. Research institutions handling these compounds should confirm their own institutional, state and federal obligations before procurement.

This page is general information, not legal advice; consult a qualified attorney for advice on any specific situation.

Which endpoints belong in a body composition study of these compounds?

A defensible design separates water, fat and contractile tissue rather than relying on a single fat-free mass number. Dual-energy X-ray absorptiometry gives regional fat and lean compartments and is the standard in the trials cited above, but it does not distinguish water from protein, which is the central interpretive problem the 2008 systematic review identified. Pairing it with a hydration measure, such as isotope dilution or multifrequency bioimpedance for total and extracellular water, lets a study test whether a lean mass change is tissue or fluid.

For fat distribution, computed tomography or magnetic resonance imaging at a standardized landmark is what the tesamorelin literature used to isolate the visceral depot, and it remains the appropriate choice when the hypothesis concerns distribution rather than total adiposity. For contractile tissue, muscle cross-sectional area by imaging, and where ethics and model permit, biopsy with myofibrillar fractional synthetic rate by stable isotope tracer, address the protein question directly. Functional endpoints should include at least one maximal force measure and one power or repeated-sprint measure, since the existing literature reports divergence between them.

Biochemical monitoring belongs in the same design: insulin-like growth factor 1 and its binding protein as pharmacodynamic markers, fasting glucose and insulin with an insulin sensitivity index because growth hormone is described as inducing insulin resistance, and standard safety chemistry. Repeated sampling over time captures the axis response that a single timepoint misses.

Finally, study architecture matters more than any single assay. Randomization, a placebo arm, a loading arm, standardized energy and protein intake and blinded assessment are what turn a set of measurements into evidence. Most of the material circulating about these compounds in performance contexts lacks all five.

What are the main limits of the current evidence?

The evidence base is thin, indirect and mostly surrogate. For CJC-1295 specifically, the human record centers on a small early-phase programme with hormonal endpoints in healthy adults, and no controlled trial has measured hypertrophy, strength or fat mass with that molecule. Everything written about the compound in a body composition context is therefore inference from the recombinant growth hormone trials, from other GHRH analogs such as tesamorelin, and from mechanism.

The inference weakens at each step. Recombinant growth hormone trials deliver a non-physiological exposure that a pituitary-dependent secretagogue cannot match, and those trials still reported no strength gains. Tesamorelin evidence comes from a clinical population defined by a specific fat distribution problem. Animal secretagogue work such as the 1998 Ipamorelin characterization describes selectivity and release, not tissue composition in a loaded model. None of these were conducted in resistance-trained adults with a controlled diet.

Duration is another limit. Body composition changes that matter accrue over months, and several of the most cited studies ran for weeks, which favors detecting fluid shifts over detecting protein accretion. Sample sizes are generally small, and the negative findings for strength carry the usual caveat that an underpowered study can miss a small effect, though the consistency of the null across reviews is itself informative.

Lastly, publication and framing bias run strongly in this area. Material that circulates in training communities tends to report favorable anecdotes without controls, while the controlled literature reports a more modest and more mixed picture. A researcher reading this field should weight randomized, placebo-controlled, diet-controlled work heavily and treat everything else as hypothesis generation.

How does Real Peptides supply CJC-1295 and Ipamorelin to laboratories?

Real Peptides supplies CJC-1295 with DAC, CJC-1295 without DAC, Ipamorelin, blended CJC-1295 and Ipamorelin research vials and Tesamorelin as catalog compounds for laboratory research use only, and publishes independent third-party certificates of analysis for every batch at /coas/. Each certificate identifies the lot it belongs to, so a purchasing laboratory can match the certificate to the material it holds rather than to a generic specification sheet. Verifying a compound's CAS number and molecular identity against the certificate before procurement is standard practice for research material and is the single most useful check a laboratory can make.

Real Peptides does not provide preparation, handling or use guidance for any catalog compound, because these are research-use-only materials and such guidance would imply a use the compounds are not supplied for. The concentration framework is the appropriate level of measurement education and is simple arithmetic: concentration equals mass divided by volume, so a vial containing a stated mass of peptide brought to a stated volume gives a nominal concentration in milligrams per milliliter. Study design, stability assessment and all handling decisions belong to the receiving institution.

For researchers building a body composition or endocrine model from the literature described on this page, the practical requirements are compound identity, lot traceability and documentation that survives audit. Shipping and facility information is listed on the locations page, and compound background pages cover identity, mechanism and published research rather than use.

All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.

References

  • Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006. PMID: 16352683
  • Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PMID: 9849822
  • Systematic review: the effects of growth hormone on athletic performance. Annals of Internal Medicine. 2008. PMID: 18347346
  • The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized controlled trial. Annals of Internal Medicine. 2010. PMID: 20439575
  • Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine. 2007. PMID: 17227934
  • Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007. PMID: 18057338
  • Effects of human growth hormone in men over 60 years old. New England Journal of Medicine. 1990. PMID: 2355952

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

Published evidence attributes muscle fiber growth to mechanical loading, not to growth hormone axis compounds alone. Controlled trials of growth hormone report lean mass changes without matching strength gains, which reviewers link partly to fluid shifts. Real Peptides supplies research-use-only compounds and gives no training or use guidance of any kind.
No published controlled trial of CJC-1295 has measured hypertrophy, strength or cross-sectional area. The 2006 Journal of Clinical Endocrinology and Metabolism study measured growth hormone, insulin-like growth factor 1 and pharmacokinetics in healthy adults. Claims about muscle gain are extrapolations from recombinant growth hormone trials, which themselves reported no strength improvement.
No trial of CJC-1295 has reported fat mass or body weight endpoints. Related GHRH analog research, including the 2007 New England Journal of Medicine tesamorelin study, reports reduced visceral adipose tissue in a specific clinical population. The broader literature describes compartment redistribution rather than large total body weight change.
The DAC modification lets the peptide bind covalently to serum albumin, extending circulation time so exposure is measured in days rather than minutes. Without DAC, the stabilized GHRH fragment clears quickly and produces a transient, pulse-like receptor stimulus. The two represent different exposure profiles, not different potencies at the receptor.
Yes. Growth hormone releasing factors and growth hormone secretagogues fall within the prohibited peptide hormone and growth factor category of the World Anti-Doping Agency Prohibited List, which applies in and out of competition. Governing bodies following the World Anti-Doping Code treat use or attempted use as an anti-doping rule violation.
No. CJC-1295 is not approved by the United States Food and Drug Administration for any indication, and under the Federal Food, Drug, and Cosmetic Act an unapproved new drug cannot be marketed for human use. Real Peptides supplies it as a research-use-only catalog compound with no human-use claim.
Because they are research-use-only materials, preparation and handling guidance would imply a use they are not supplied for. The appropriate education is the concentration framework: concentration equals mass divided by volume, giving a nominal figure in milligrams per milliliter that a laboratory converts to its own per-assay working scale.
Dual-energy X-ray absorptiometry for regional fat and lean compartments, paired with a hydration measure so fluid is separated from tissue, plus imaging for visceral depots and for muscle cross-sectional area. Insulin-like growth factor 1 serves as a pharmacodynamic marker, and glucose and insulin measures capture metabolic effects.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now